# Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

> **NCT05310591** · PHASE1,PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 26 (estimated)

## Conditions studied

- B Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia, in Relapse

## Interventions

- **DRUG:** Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )
- **DRUG:** Nivolumab starting at day -1

## Key facts

- **NCT ID:** NCT05310591
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05310591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05310591, "Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05310591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*